PT2609082E - Imidazo[4,5-c]quinolinas como inibidores de dna-pk - Google Patents
Imidazo[4,5-c]quinolinas como inibidores de dna-pk Download PDFInfo
- Publication number
- PT2609082E PT2609082E PT117482604T PT11748260T PT2609082E PT 2609082 E PT2609082 E PT 2609082E PT 117482604 T PT117482604 T PT 117482604T PT 11748260 T PT11748260 T PT 11748260T PT 2609082 E PT2609082 E PT 2609082E
- Authority
- PT
- Portugal
- Prior art keywords
- quinolines
- imidazo
- inhibitors
- dna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010035744A DE102010035744A1 (de) | 2010-08-28 | 2010-08-28 | Imidazolonylchinoline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2609082E true PT2609082E (pt) | 2015-06-05 |
Family
ID=44509164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT117482604T PT2609082E (pt) | 2010-08-28 | 2011-07-26 | Imidazo[4,5-c]quinolinas como inibidores de dna-pk |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9000153B2 (pt) |
| EP (1) | EP2609082B1 (pt) |
| JP (1) | JP5882329B2 (pt) |
| KR (1) | KR101912475B1 (pt) |
| CN (1) | CN103068803B (pt) |
| AR (1) | AR082728A1 (pt) |
| AU (1) | AU2011298013B9 (pt) |
| BR (1) | BR112013004613B1 (pt) |
| CA (1) | CA2809553C (pt) |
| CY (1) | CY1116281T1 (pt) |
| DE (1) | DE102010035744A1 (pt) |
| DK (1) | DK2609082T3 (pt) |
| EA (1) | EA022095B1 (pt) |
| ES (1) | ES2536313T3 (pt) |
| HK (1) | HK1184154A1 (pt) |
| HR (1) | HRP20150489T1 (pt) |
| HU (1) | HUE025692T2 (pt) |
| IL (1) | IL224903A (pt) |
| MX (1) | MX338150B (pt) |
| PL (1) | PL2609082T3 (pt) |
| PT (1) | PT2609082E (pt) |
| RS (1) | RS54038B1 (pt) |
| SG (1) | SG187954A1 (pt) |
| SI (1) | SI2609082T1 (pt) |
| WO (1) | WO2012028233A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106977495B (zh) | 2012-04-24 | 2020-08-04 | 沃泰克斯药物股份有限公司 | Dna-pk抑制剂 |
| ES2900061T3 (es) | 2013-03-12 | 2022-03-15 | Vertex Pharma | Inhibidores de DNA-PK |
| EP3424920B1 (en) | 2013-10-17 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
| NO2714752T3 (pt) | 2014-05-08 | 2018-04-21 | ||
| ES2946507T3 (es) * | 2015-04-02 | 2023-07-20 | Merck Patent Gmbh | Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
| WO2018183868A1 (en) * | 2017-03-31 | 2018-10-04 | Bioventures, Llc | Inhibitors of dna pk and uses thereof |
| ES2925801T3 (es) * | 2017-08-11 | 2022-10-19 | Merck Patent Gmbh | Preparación farmacéutica que comprende 3-fluoro-4-[7-metoxi-3-metil-8-(1-metil-1H-pirazol-4-il)-2-oxo-2,3-dihidro-imidazo[4,5-c]quinolin-1-il]-benzonitrilo |
| WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| EP3765019A1 (en) | 2018-03-14 | 2021-01-20 | Merck Patent GmbH | Compounds and uses thereof to treat tumors in a subject |
| TWI820146B (zh) | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
| CN111909144A (zh) * | 2019-05-10 | 2020-11-10 | 山东轩竹医药科技有限公司 | 喹唑啉类dna-pk抑制剂 |
| MX2022000358A (es) | 2019-07-10 | 2022-02-03 | Merck Patent Gmbh | Preparacion farmaceutica. |
| US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
| US20230044248A1 (en) | 2019-11-01 | 2023-02-09 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| US20230226041A1 (en) | 2020-06-18 | 2023-07-20 | Merck Patent Gmbh | Compounds for the treatment of viral infections |
| CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2074867T3 (es) | 1990-11-06 | 1995-09-16 | Pfizer | Derivados de quinazolina para potenciar la actividad antitumoral. |
| WO2000061186A1 (en) | 1999-04-08 | 2000-10-19 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| NZ540826A (en) * | 2002-12-20 | 2008-07-31 | 3M Innovative Properties Co | Aryl / hetaryl substituted imidazoquinolines |
| NZ545412A (en) * | 2003-08-27 | 2008-12-24 | Coley Pharm Group Inc | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| BRPI0414856A (pt) * | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | imidazoquinolinas alcóxi-substituìdas |
| AR046845A1 (es) * | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
| CN1830964B (zh) * | 2005-03-11 | 2011-06-15 | 中国科学院上海药物研究所 | 4-取代苯氨基-3-硝基喹啉类化合物及其制备方法和用途 |
| AR054438A1 (es) * | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JP5247458B2 (ja) * | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法 |
| US8436177B2 (en) * | 2006-11-20 | 2013-05-07 | Novartis Ag | Salts and crystall forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
| US20110130386A1 (en) | 2008-04-25 | 2011-06-02 | Mark Frigerio | Dna-pk inhibitors |
| EP2303890A4 (en) | 2008-06-19 | 2012-04-11 | Progenics Pharm Inc | INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE |
| JP5347628B2 (ja) * | 2009-03-26 | 2013-11-20 | 富士通株式会社 | マイクロ構造体 |
| WO2010139747A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| CA2763821A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | 1h-imidazo[4,5-c]quinolinone derivatives |
| WO2011001212A1 (en) * | 2009-06-30 | 2011-01-06 | Piramal Life Sciences Limited | Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation |
-
2010
- 2010-08-28 DE DE102010035744A patent/DE102010035744A1/de not_active Withdrawn
-
2011
- 2011-07-26 DK DK11748260.4T patent/DK2609082T3/en active
- 2011-07-26 CN CN201180041966.4A patent/CN103068803B/zh active Active
- 2011-07-26 PL PL11748260T patent/PL2609082T3/pl unknown
- 2011-07-26 SG SG2013013966A patent/SG187954A1/en unknown
- 2011-07-26 JP JP2013526334A patent/JP5882329B2/ja active Active
- 2011-07-26 KR KR1020137006794A patent/KR101912475B1/ko active IP Right Grant
- 2011-07-26 RS RS20150330A patent/RS54038B1/en unknown
- 2011-07-26 EP EP11748260.4A patent/EP2609082B1/de active Active
- 2011-07-26 US US13/819,488 patent/US9000153B2/en active Active
- 2011-07-26 ES ES11748260.4T patent/ES2536313T3/es active Active
- 2011-07-26 SI SI201130493T patent/SI2609082T1/sl unknown
- 2011-07-26 EA EA201300288A patent/EA022095B1/ru not_active IP Right Cessation
- 2011-07-26 CA CA2809553A patent/CA2809553C/en active Active
- 2011-07-26 AU AU2011298013A patent/AU2011298013B9/en active Active
- 2011-07-26 HU HUE11748260A patent/HUE025692T2/en unknown
- 2011-07-26 PT PT117482604T patent/PT2609082E/pt unknown
- 2011-07-26 WO PCT/EP2011/003744 patent/WO2012028233A1/de active Application Filing
- 2011-07-26 BR BR112013004613-9A patent/BR112013004613B1/pt active IP Right Grant
- 2011-07-26 MX MX2013002259A patent/MX338150B/es active IP Right Grant
- 2011-08-26 AR ARP110103113A patent/AR082728A1/es active IP Right Grant
-
2013
- 2013-02-25 IL IL224903A patent/IL224903A/en active IP Right Grant
- 2013-10-17 HK HK13111720.9A patent/HK1184154A1/zh unknown
-
2015
- 2015-04-01 US US14/676,125 patent/US9598408B2/en active Active
- 2015-05-07 HR HRP20150489TT patent/HRP20150489T1/hr unknown
- 2015-05-14 CY CY20151100429T patent/CY1116281T1/el unknown
-
2017
- 2017-02-27 US US15/443,349 patent/US20170166567A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL224903A (en) | Imidzo [c – 5,4] quinolines as DNA inhibitors | |
| AP2806A (en) | 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-infammatory agents | |
| IL234485A (en) | Compounds based on imidazo [2,1 – b] pyridazine | |
| HK1180689A1 (en) | Imidazopyridines syk inhibitors syk | |
| IL221823A (en) | Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors | |
| EP2608669A4 (en) | NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER | |
| HK1199018A1 (zh) | 作為 抑制劑的吡唑並喹啉衍生物 | |
| ZA201203326B (en) | Imidazopyridine derivatives as jak inhibitors | |
| ZA201304757B (en) | Imidazo [4,5-c] quinolin-2-one compound and its use as p13 kinase/mtor dual inhibitor | |
| HK1189223A1 (zh) | 用作β分泌酶 抑制劑的 -二氫-吡咯並 吡嗪- -基胺衍生物 | |
| ZA201108439B (en) | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | |
| EP2634186A4 (en) | naphthyridine | |
| EP2563125A4 (en) | AZAINDOLE AS JANUSKINASE HEMMER | |
| GB201016880D0 (en) | Phosphodiesterase inhibitors | |
| IL218032A0 (en) | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors | |
| ZA201206630B (en) | Hetaryl-[1,8]naphthyridine derivatives | |
| EP2525659A4 (en) | PYRAZOLO [1,5-A] PYRIMIDINES COMPOUNDS AS MTOR INHIBITORS | |
| IL214426A0 (en) | [1,2,4] triazollo [1,5-a] pyridines as kinase inhibitors | |
| IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
| SI2588457T1 (sl) | Derivati pirazolokinolina kot inhibitorji dna pk | |
| IL235829A0 (en) | Triazolo compounds as pde10 inhibitors | |
| IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
| EP2523552A4 (en) | PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER | |
| EP2565194A4 (en) | Imidazo [1,2-A] pyridine | |
| EP2490693A4 (en) | Pyrazolo [3,4-B] PYRIDINE-4-ON-KINASE INHIBITORS |